Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein

Journal of Virology

Volumn 71, Issue 12, 1997, Pages 9475-9481

  Jurkiewicz, Elke ^a   Hunsmann, Gerhard ^a   Schäffner, Jörg ^a   Nisslein, Thomas ^a   Lüke, Wolfgang ^a   Petry, Harald ^a  

^a GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD TRANSFUSION; GENETIC VARIABILITY; IMMUNIZATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS ISOLATION;

EID: 0030731413     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.12.9475-9481.1997     Document Type: Article

References (65)

1. Almond, N., A. Jenkins, A. B. Heath, and P. Kitchin. 1993. Sequence varition in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1-region. J. Gen. Virol. 74:865-871.
2. Babas, T., B. Belhadj-Jrad, R. Le Grand, D. Dormont, L. Montagnier, and E. Bahraoui. 1995. Specificity and neutralizing capacity of the three monoclonal antibodies produced against the envelope glycoprotein of simian immunodeficiency virus isolate 251. Virology 211:339-344.
3. Benichou, S., R. Legrand, N. Nakagawa, T. Faure, F. Traincard, G. Vogt, D. Dormont, P. Tiollais, M.-P. Kieny, and P. Madaule. 1992. Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 8:1165-1170.
4. Broliden, P.-A., A. von Gegerfeld, P. Clapham, J. Rosen, E.-M. Fenyö, B. Wahren, and K. Broliden. 1992. Identification of human neutralizing-inducing regions of the human immunodeficiency virus type 1 envelope grycoproteins Proc. Natl. Acad. Sci. USA 89:461-465.
5. Chackerian, B., W. R. Morton, and J. Overbaugb. 1994. Persistence of simian immunodeficiency virus Mne variants upon transmission. J. Virol. 68:4080-4085.
6. Chanh, T., G. Dreesman, P. Kanda, G. Linette, J. Sparrow, D. Ho, and R. Kennedy. 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 5:3065-3071.
7. Cranage, M. P., N. Cook, P. Johnstone, P. J. Greenaway, P. A. Kitchin, E. J. Stott, N. Almond, and A. Baskerville. 1990. SIV infection of macaques: in vivo titration of infectivity and development of an experimental vaccine, p. 103-114. In H. Schellekens and M. C. Horzinek (ed.), Animal models in AIDS. Elsevier, Amsterdam, The Netherlands.
8. Desrosiers, R. C. 1990. The simian immunodeficiency viruses. Annu. Rev. Immunol. 8:557-578.
9. Emini, E. A., P. L. Nara, W. A. Schleif, J. A. Lewis, J. P. Davide, D. R. Lee, J. Kessler, S. Conley, S. Matsushita, S. D. Putney, R. J. Gerety, and J. W. Eichberg. 1990. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64:3674-3678.
10. Emini, E. A., W. A. Schleif, J. H. Nürnberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
11. Fung, M. S. C., C. R. Y. Sun, W. L. Gordon, R.-S. Liou, T. W. Chang, W. N. C. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
12. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
13. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, and D. C. Gaidusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
14. Haigwood, N., L. Misher, S. M. Chin, M. Blair, V. Planelles, C. J. Scandella, K. S. Steimer, M. B. Gardner, T. Yilma, and P. R. Johnson. 1992. Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J. Med. Primatol. 21:82-90.
15. Harada, S., D. T. Purtilo, Y. Koyanagi, J. Sonnabend, and N. Yamamoto. 1986. Sensitive assay for neutralizing antibodies against AIDS related viruses (HTLV-III/LAV). J. Immunol. Methods 92:177-181.
16. Hartmann, H., M. W. Vogt, A. G. Durno, M. S. Hirsch, G. Hunsmann, and F. Eckstein. 1988. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogues AIDS Res. Hum. Retroviruses 4:457-466.
17. Ho, D. D., M. G. Sarngadharan, M. S. Hirsch, R. T. Schooley, T. R. Rota, R. C. Kennedy, T. C. Chanh, and V. L. Sato. 1987. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61:2024-2028.
18. Ho, D. D., M. S. C. Fung, Y. Cao, C. Sun, T. W. Chang, and N. C. Sun. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
19. Javaherian, K., A. J. Langlois, C. McDanal, K. L. Ross, L. I. Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
20. Javaherian, K., A. J. Langlois, S. Schmidt, M. Kaufmann, N. Cates, J. P. M. Langedijk, R. H. Meloen, R. C. Desrosiers, D. P. W. Burns, D. P. Bolognesi, G. J. LaRosa, and S. Putney. 1992. The principle neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 89:1418-1422.
21. Javaherian, K., A. J. Langlois, D. C. Monteftori, K. A. Kent, K. A. Ryan, P. D. Wyman, J. Stott, D. P. Bolognesi, M. Murphey-Corb, and G. J. Larosa. 1994. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J. Virol. 68:2624-2631.
22. Jurkiewicz, E., P. Panse, K. D. Jentsch, H. Hartmann, and G. Hunsmann. 1989. In vitro anti-HIV-1 activity of chondroitin polysulphate. AIDS 3:423-427.
23. Jurkiewicz, E., R. Jansen, W. Trowitzsch-Kienast, B. Kunze, E. Forche, H. Reichenbach, G. Höfle, and G. Hunsmann. 1992. Three new potent HIV-1 inhibitors from myxobacteria. Antivir. Chem. Chemother. 3:189-193.
24. Jurkiewicz, E., H. Petry, I. Schedel, G. C. Sutor, S. Lang, and G. Hunsmann. 1995. HIV-1 cross-neutralizing antibodies in German HIV-1 infected patients do not correlate with an antibody binding pattern against different HIV-1 isolates. AIDS 9:91-93.
25. Kayman, S. C., Z. Wu, K. Revesz, H. C. Chen, R. Kopelman, and A. Pinter. 1994. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 68:400-410.
26. Kent, K. A., E. Rud, T. Corcoran, C. Powell, C. Thiriart, C. Collognon, and E. J. Stott 1992. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res. Hum. Retroviruses 8:1147-1151.
27. Kent, K. A., P. Kitchin, K. H. G. Mills, M. Page, F. Taffs, T. Corcoran, P. Silvera, B. Flanagan, C. Powell, J. Rose, C. Ling, A. M. Aabertin, and E. J. Stott. 1994. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res. Hum. Retroviruses 10:189-194.
28. Kikukawa, R., Y. Kojanagy, S. Harada, N. Kobayashi, M. Hatanaka, and N. Yamamoto. 1986. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells from human leukemic T-cell line Molt-4. J. Virol. 57:1159-1162.
29. Kirchhoff, F., K. D. Jentsch, B. Bachmann, A. Stuke, C. Laloux, W. Lüke, C. Stahl-Hennig, J. Schneider, K. Nieselt, M. Eigen, and G. Hunsmann. 1990. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology 177:305-311.
30. Kodama, T., D. P. W. Burns, D. P. Silva, F. DiMarzo Veronese, and R. C. Desrosiers. 1991. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus. J. Virol. 65:2010-2018.
31. LaRosa, G. J., J. P. Davide, K. Weinhold, J. A. Waterbury, A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreesman, R. N. Boswell, P. Shaddock, L. Howard Holley, M. Karplus, D. P. Bolognesi, T. J. Matthews, E. A. Emini, and S. D. Putney. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935.
32. Lewis, M. G., W. R. Elkins, F. E. McCutchan, R. E. Benveniste, C. Y. Lai, D. C. Montefiori, D. S. Burke, G. A. Eddy, and A. Shafferman. 1993. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11:1347-1355.
33. Lüke, W., G. Voss, C. Stahl-Hennig, C. Coulibaly, P. Putkonen, H. Petry, and G. Hunsmann. 1993. Protection of cynomolgus macaques (Macaca fascicularis) against infection with the human immunodeficiency virus type 2 strain ben (HIV-2ben) by immunization with the virion-derived envelope glycoprotein gp130. AIDS Res. Hum. Retroviruses 9:1013-1018.
34. Lüke, W., C. Stahl-Hennig, G. Voss, U. Dittmer, W. Bodemer, B. Makoschey, E. Jurkiewicz, H. Petry, C. Coulibaly, and G. Hunsmann. 1994. Immunization with virus-derived gp130 micelles protects rhesus monkeys against challenge with SIVmac251/32H either grown on human T-cells or prepared directly from the spleen of an SIV-infected rhesus monkey, p. 231-235. In F. Brown et al. (ed.), Vaccines 94: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
35. Lüke, W., C. Coulibaly, U. Dittmer, G. Voss, R. Oesterle, B. Makoschey, U. Sauermann, E. Jurkiewicz, C. Stahl-Hennig, H. Petry, and G. Hunsmann. 1996. Simian immunodeficiency virus (SIV) gp130-oligomers protect rhesus macaques (Macaca mulatta) against infection with SIVmac32H grown on T-cells or derived ex vivo. Virology 216:444-450.
36. Lüke, W., H. Petry, U. Dittmer, G. Farrar, D. Fuchs, T. Nißlein, E. Jurkiewicz, C. Stahl-Hennig, and G. Hunsmann. A subunit vaccine consisting of gp130 oligomers but not of gp130 monomers partially protects rhesus macaques (Macaca mulatta) against the productive infection with SIVmac32H and suppresses efficiently disease development. Submitted for publication.
37. Matsumi, S., S. Matsushita, K. Yoshimura, K. Javaherian, and K. Takatsuki. 1995. Neutralizing monoclonal antibody against an external envelope glycoprotein (gp110) of SIVmac251. AIDS Res. Hum. Retroviruses 11:501-508.
38. McBride, B. W., G. Corthals, E. Rud, K. Kent, S. Webster, N. Cook, and M. P. Cranage. 1993. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination. J. Gen. Virol. 74:1033-1041.
39. Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi. K. Nagata, and Y. Hinuma. 1981. Detection of type C virus particles in a cord T-cell line derived by cocultivation of normal human leucocytes and human leukemic T-cells. Nature 294:770-771.
40. Moore, J. P., Q. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S.-W. Poon, M. S. Fung, F. Traincard, J. E. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of the human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: the immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
41. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6624-6647.
42. Otteken, A., G. Voss, and G. Hunsmann. 1993. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia virus. Virology 194:37-43.
43. Overbaugh, J., L. M. Rudensey, M. D. Papenhausen, R. E. Benveniste, and W. R. Morton. 1991. Variation in the simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J. Virol. 65: 7025-7031.
44. Overbaugh, J., and L. M. Rudensey. 1992. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J. Virol. 66:5937-5948.
45. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Hayes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932-1936.
46. Palker, T. J., A. J. Muir, D. E. Spragion, H. F. Staats, A. Langlois, and D. C. Monteflori. 1996. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology 224:415-426.
47. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
48. Petry, H., U. Dittmer, C. Stahl-Hennig, C. Coulibaly, B. Makoschey, D. Fuchs, H. Wachter, T. Tolle, C. Morys-Wortmann, F.-J. Kaup, E. Jurkiewicz, W. Lüke, and G. Hunsmann. 1995. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection. J. Virol. 69:1564-1574.
49. Putkonen, P., R. Thorstensson, L. Ghavamzadeh, J. Albert, K. Hild, G. Biberfeld, and E. Norrby. 1991. Prevention of HIV-1 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352:436-438.
50. Robert-Guroff, M., K. Aldrich, R. Muldoon, T. L. Stern, G. P. Bansal, T. J. Matthews, P. D. Markham, R. C. Gallo, and G. Franchini. 1992. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J. Virol. 66:3602-3608.
51. Rudensey, L. M., J. T. Kimata, R. E. Beneviste, and J. Overbaugh. 1995. Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology 207:528-542.
52. Rusche, J. A., K. Javaherian, C. McDanal, J. Petro, D. L. Lynn, R. Grimaila, A. Langlois, R. C. Gallo, L. O. Athur, P. J. Fischinger, D, P. Bolognesi, S. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA 85:3198-3202.
53. Schäffner, J.-W., U. Dittmer, A. Otteken, C. Coulibaly, W. Bodemer, G. Voss, and G. Hunsmann. 1994. Comparison of humoral immunity and induction of proliferating T lymphocytes in vaccinia virus-infected rabbits and rhesus macaques. Am. J. Vet. Res. 55:1250-1255.
54. Schneider, J., W. Lüke, F. Kirchhoff, R. Jung, E. Jurkiewicz, C. Stahl-Hennig, S. Nick, E. Klemm, K. D. Jentsch, and G. Hunsmann. 1990. Isola-tion and characterization of HIV-2ben obtained from a patient with pre-dominantly neurological defects. AIDS 4:455-457.
55. Silvera, P., B. Flanagan, K. Kent, E. Rud, C. Powell, T. Corcoran, C. Bruck, C. Thiriart, N. L. Haigwood, and E. J. Stott. 1994. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res. Hum. Retroviruses 10:1295-1304.
56. Stahl-Hennig, C., G. Voss, U. Dittmer, C. Coulibaly, H. Petry, B. Makoschey, M. P. Cranage, A. M. Aubertin, W. Luke, and G. Hunsmann. 1993. Protec-tion of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS 7:787-795.
57. Stahl-Hennig, C., C. Coulibaly, H. Petry, G. Voss, U. Dittmer, W. Bodemer, B. Makoschey, E. Jurkiewicz, W. Lüke, and G. Hunsmann. 1994. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. AIDS Res. Hum. Retroviruses 10:527-532.
58. Sullivan, N. M. Thali, C. Furman, D. D. Ho, and J. Sodroski. 1993. Effect of amino acid exchanges in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67:3674-3679.
59. Sutor, G.-C., U. Dreukhausen, U. Vähning, E. Jurkiewicz, G. Hunsmann, K. Lundin, and I. Schedel. 1992. Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD-4. J. Immunol. 149:1452-1461.
60. Tolle, T., H. Petry, B. Bachmann, G. Hunsmann, and W. Lüke. 1994. Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben. J. Virol. 68:2765-2771.
61. Torres, J. V., A. Malley, B. Banapour, D. E. Anderson, M. B. Axthelm, M. B. Gardner, and E. Benjamini. 1993. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. AIDS Res. Hum. Retroviruses 9:423-430.
62. Voss, G., C. Stahl-Hennig, H. Petry, C. Coulibaly, S. Nick, D. Fuchs, H. Wachter, W. Lüke, and G. Hunsmann. 1992. Immunization of rhesus monkeys with high-and low-dose Tween-ether-disrupted SIVmac. AIDS Res. Hum. Retroviruses 8:1397-1400.
63. Voss, G., U. Dittmer, C. Coulibaly, B. Makoschey, H. Petry, W. Lüke, and G. Hunsmann. 1993. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. J. Gen. Virol. 74:1757-1763.
64. Wendler, I., U. Bienzle, and G. Hunsmann. 1987. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res. Hum. Retroviruses 3:157-163.
65. Wu, Z., S. C. Kayman, W. Honnen, K. Revesz, H. Chen, S. Vijh-Warrier, S. A. Tilley, J. McKeating, C. Shotton, and A. Pinter. 1995. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J. Virol. 69:2271-2278.